Suppr超能文献

青霉胺肾病的自然病程:33例患者的长期研究

Natural course of penicillamine nephropathy: a long term study of 33 patients.

作者信息

Hall C L, Jawad S, Harrison P R, MacKenzie J C, Bacon P A, Klouda P T, MacIver A G

机构信息

Department of Renal Medicine, Royal United Hospital, Bath.

出版信息

Br Med J (Clin Res Ed). 1988 Apr 16;296(6629):1083-6. doi: 10.1136/bmj.296.6629.1083.

Abstract

To elucidate the natural course of the nephropathy associated with penicillamine and thereby facilitate its clinical management 33 patients with rheumatoid arthritis who developed proteinuria during treatment with oral penicillamine were studied in detail throughout their renal illness. Renal biopsies were performed, and creatinine clearance and proteinuria were measured serially for 74 months (range 16-148 months). Fourteen patients developed proteinuria within six months after the start of treatment and 27 within 12 months. When treatment was stopped the proteinuria reached a median peak of 4.2 g/24 h (range 0.3-15.0 g/24 h) at one month (range 0-7 months) before resolving spontaneously by six months (12 patients), 12 months (21), or 18 months (29). In all patients but one, who developed carcinoma of the renal pelvis, proteinuria resolved by 21 months and its median duration was eight months. The median first and last measurements of creatinine clearance showed no appreciable change (80 ml/min and 78 ml/min), and no patient died from or needed treatment for renal failure. The HLA-B8 or HLA-DR3 alloantigen, or both, were identified in 10 patients. Renal biopsy specimens showed membranous glomerulonephritis in 29 patients, minimal change nephropathy in two, and electron dense deposits in the mesangial regions in two. In all the patients whose nephropathy was due solely to treatment with penicillamine the proteinuria resolved completely when the drug was withdrawn; renal function did not deteriorate, and corticosteroids were unnecessary.

摘要

为阐明与青霉胺相关的肾病的自然病程,从而促进其临床管理,我们对33例在口服青霉胺治疗类风湿关节炎过程中出现蛋白尿的患者在整个肾脏疾病过程中进行了详细研究。进行了肾活检,并连续74个月(范围16 - 148个月)测量肌酐清除率和蛋白尿。14例患者在治疗开始后6个月内出现蛋白尿,27例在12个月内出现。当停止治疗时,蛋白尿在1个月(范围0 - 7个月)时达到中位数峰值4.2 g/24小时(范围0.3 - 15.0 g/24小时),然后在6个月(12例患者)、12个月(21例)或18个月(29例)时自发缓解。除1例发生肾盂癌的患者外,所有患者的蛋白尿在21个月内缓解,其持续时间中位数为8个月。肌酐清除率的首次和末次测量中位数无明显变化(分别为80 ml/min和78 ml/min),且无患者因肾衰竭死亡或需要治疗。10例患者鉴定出HLA - B8或HLA - DR3同种抗原,或两者皆有。肾活检标本显示29例为膜性肾小球肾炎,2例为微小病变肾病,2例在系膜区有电子致密沉积物。在所有仅因青霉胺治疗导致肾病的患者中,停药后蛋白尿完全缓解;肾功能未恶化,无需使用皮质类固醇。

相似文献

1
Natural course of penicillamine nephropathy: a long term study of 33 patients.
Br Med J (Clin Res Ed). 1988 Apr 16;296(6629):1083-6. doi: 10.1136/bmj.296.6629.1083.
2
The natural course of gold and penicillamine nephropathy: a longterm study of 54 patients.
Adv Exp Med Biol. 1989;252:247-56. doi: 10.1007/978-1-4684-8953-8_23.
3
The natural course of gold nephropathy: long term study of 21 patients.
Br Med J (Clin Res Ed). 1987 Sep 26;295(6601):745-8. doi: 10.1136/bmj.295.6601.745.
7
Penicillamine nephropathy.
Nephron. 1980;26(4):184-6. doi: 10.1159/000181984.
8
Penicillamine-induced proteinuria: risk factors.
Semin Arthritis Rheum. 1986 May;15(4):282-7. doi: 10.1016/0049-0172(86)90023-5.
9
Effect of penicillamine on the kidney.
Proc R Soc Med. 1977;70 Suppl 3(Suppl 3):109-13. doi: 10.1177/00359157770700S334.

引用本文的文献

1
Drug-Induced Renal Vasculitis: Etiology, Pathogenesis, Clinical Manifestations, and Therapeutic Approaches-A Narrative Review.
Health Sci Rep. 2025 Apr 16;8(4):e70667. doi: 10.1002/hsr2.70667. eCollection 2025 Apr.
2
Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective.
J Clin Med. 2024 Aug 18;13(16):4869. doi: 10.3390/jcm13164869.
3
Kidney involvement in Wilson's disease: a review of the literature.
Clin Kidney J. 2024 Mar 9;17(4):sfae058. doi: 10.1093/ckj/sfae058. eCollection 2024 Apr.
4
Challenges and dilemmas in pediatric hepatic Wilson's disease.
World J Hepatol. 2023 Oct 27;15(10):1109-1126. doi: 10.4254/wjh.v15.i10.1109.
5
Drug-Induced Podocytopathies: Report of Four Cases and Review of the Literature.
Life (Basel). 2023 May 26;13(6):1264. doi: 10.3390/life13061264.
6
Chelation therapy in liver diseases of childhood: Current status and response.
World J Hepatol. 2021 Nov 27;13(11):1552-1567. doi: 10.4254/wjh.v13.i11.1552.
7
Clinical manifestations of Wilson disease in organs other than the liver and brain.
Ann Transl Med. 2019 Apr;7(Suppl 2):S62. doi: 10.21037/atm.2019.03.30.
8
Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease.
Kidney Int. 2018 May;93(5):1207-1216. doi: 10.1016/j.kint.2017.11.025. Epub 2018 Mar 2.
9
End-Stage Kidney Disease From Scleroderma in the United States, 1996 to 2012.
Kidney Int Rep. 2017 Sep 18;3(1):148-154. doi: 10.1016/j.ekir.2017.09.003. eCollection 2018 Jan.
10
Drug-induced glomerular disease: immune-mediated injury.
Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1300-10. doi: 10.2215/CJN.01910215. Epub 2015 Jun 19.

本文引用的文献

1
Penicillamine nephropathy.
Nephron. 1980;26(4):184-6. doi: 10.1159/000181984.
3
Penicillamine in rheumatoid disease: a long-term study.
Br Med J. 1974 Feb 2;1(5900):180-3. doi: 10.1136/bmj.1.5900.180.
5
Letter: Goodpasture syndrome and D-penicillamine.
Ann Intern Med. 1976 Jan;84(1):100. doi: 10.7326/0003-4819-84-1-100_1.
8
Membranous nephropathy in patients with rheumatoid arthritis: relationship to gold therapy.
Medicine (Baltimore). 1978 Jul;57(4):319-27. doi: 10.1097/00005792-197807000-00003.
10
Penicillamine in rheumatoid arthritis: clinical pharmacology and biochemical properties.
Scand J Rheumatol Suppl. 1979(28):58-64. doi: 10.3109/03009747909108238.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验